Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) shares saw unusually-strong trading volume on Wednesday . Approximately 162,046 shares were traded during trading, an increase of 225% from the previous session’s volume of 49,907 shares.The stock last traded at $14.03 and had previously closed at $13.63.
Analyst Ratings Changes
Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Monday, October 27th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy”.
Read Our Latest Stock Analysis on Fresenius SE & Co.
Fresenius SE & Co. Stock Performance
Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.02. Fresenius SE & Co. had a net margin of 5.26% and a return on equity of 9.72%. The company had revenue of $6.29 billion during the quarter, compared to analysts’ expectations of $6.38 billion. On average, analysts forecast that Fresenius SE & Co. will post 0.79 EPS for the current year.
About Fresenius SE & Co.
Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Further Reading
- Five stocks we like better than Fresenius SE & Co.
- Dividend Payout Ratio Calculator
- Synopsys Sees Bullish Shift as Ansys Integration Drives Growth
- Top Stocks Investing in 5G Technology
- The Best Holiday Present You Can Give Yourself? Costco Stock
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
